BAIL FDA

BAIL FDA models bioaerosol deposition in human lungs to predict particle deposition patterns and support exposure and risk assessment for pathogenic aerosols.

Key Features:

• ICRP Publication 66 adaptation: Implements an adapted International Committee for Radiological Protection (ICRP) Publication 66 lung deposition model for application to bioaerosols.
• Pathogen-specific modeling: Calculates deposition for monodisperse pathogenic toxins including botulinum toxin, influenza virus, and Bacillus anthracis.
• Age-dependent analysis: Models deposition across age groups, explicitly including infants and adults.
• Customizable model parameters: Provides a template to adjust model parameters and scenario-specific settings for tailored analyses.

Scientific Applications:

• Public health preparedness: Supports assessment of inhalation risks from pathogenic bioaerosols to inform preparedness strategies.
• Research on bioaerosol behavior: Enables studies of lung deposition patterns for different pathogens and particle sizes.
• Policy and risk assessment: Informs policymakers and risk assessors about potential health impacts of aerosolized pathogens.

Methodology:

Adaptation of the ICRP Publication 66 lung deposition model applied to bioaerosol contexts, with explicit handling of monodisperse particles and age-dependent lung parameters (infants and adults).